From blockbuster to nichebuster - Niche therapies drive future drugs growth and incentivize R&D investment over sales spending

> Overview of the role that blockbusters have played in shaping and driving market growth

> Identification of which niche disease markets to target, to maximize value from the nichebuster model

> Examination of how a range of different drivers such as regulatory initiatives are incentivizing the nichebuster model

> Identification of trends underlying R&D collaborations or licensing deal activity in allowing Big Pharma to access novel technologies and markets

Report Highlights

> To successfully capitalize on the nichebuster model, drugs companies should focus on characterizing the target market, and use targeted marketing spend to access specialist physicians to drive clinical trial progression, approval and successful uptake

> Dependence on blockbuster-generated revenue is set to fall from 2004-2010 as the industry turns to a nichebuster strategy, utilizing increased licensing activity, R&D collaborations and small-scale M&A deals to harness innovation and provide access to niche markets with a high unmet need

> The shift into niche markets is helping drive a more personalized approach to therapy. Central to the development of the nichebuster model is the raised importance of personalized therapies, which is being driven by increased used of diagnostics. This trend is helping to clarify market segmentation and will boost the size of the total drug industry

Reasons to Purchase

> Identify why blockbusters have played such an important role in pharma/biotech market development

> Understand why it is no longer optimal for this strategy to play a central role in driving future growth

> Gain insight into how the transition towards the nichebuster model will change overall market dynamics in the future

24-Jul-06 PDF 46
Table of Contents
Price: $1,900.00 / GBP1,254.00